Gatekeeping testing via adaptive alpha allocation.
In a typical clinical trial, there are one or two primary endpoints, and a few secondary endpoints. When at least one primary endpoint achieves statistical significance, there is considerable interest in using results for the secondary endpoints to enhance characterization of the treatment effect. Because multiple endpoints are involved, regulators may require that the familywise type I error rate be controlled at a pre-set level. This requirement can be achieved by using "gatekeeping" methods. However, existing methods suffer from logical oddities such as allowing results for secondary endpoint(s) to impact the likelihood of success for the primary endpoint(s). We propose a novel and easy-to-implement gatekeeping procedure that is devoid of such deficiencies. A real data example and simulation results are used to illustrate efficiency gains of our method relative to existing methods.